➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
McKinsey
Boehringer Ingelheim
Merck
Moodys

Last Updated: August 3, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PEMAZYRE

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for PEMAZYRE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT04659616 ↗ Pemigatinib in Combination With Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia Not yet recruiting Incyte Corporation Phase 1 2020-12-21 This phase I trial identifies the best dose and clinical benefit of adding pemigatinib to the treatment regimen following standard induction chemotherapy in patients with newly diagnosed acute myeloid leukemia. Pemigatinib selectively inhibits FGFR (fibroblast growth factor receptor) activity, a receptor that may contribute to the growth of leukemia cells. The genetic changes responsible for activating the growth of leukemia cells can be unique to each patient and can change during the course of the disease. Chemotherapy drugs, such as cytarabine and daunorubicin work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
NCT04659616 ↗ Pemigatinib in Combination With Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia Not yet recruiting Oregon Health and Science University Phase 1 2020-12-21 This phase I trial identifies the best dose and clinical benefit of adding pemigatinib to the treatment regimen following standard induction chemotherapy in patients with newly diagnosed acute myeloid leukemia. Pemigatinib selectively inhibits FGFR (fibroblast growth factor receptor) activity, a receptor that may contribute to the growth of leukemia cells. The genetic changes responsible for activating the growth of leukemia cells can be unique to each patient and can change during the course of the disease. Chemotherapy drugs, such as cytarabine and daunorubicin work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
NCT04659616 ↗ Pemigatinib in Combination With Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia Not yet recruiting OHSU Knight Cancer Institute Phase 1 2020-12-21 This phase I trial identifies the best dose and clinical benefit of adding pemigatinib to the treatment regimen following standard induction chemotherapy in patients with newly diagnosed acute myeloid leukemia. Pemigatinib selectively inhibits FGFR (fibroblast growth factor receptor) activity, a receptor that may contribute to the growth of leukemia cells. The genetic changes responsible for activating the growth of leukemia cells can be unique to each patient and can change during the course of the disease. Chemotherapy drugs, such as cytarabine and daunorubicin work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for PEMAZYRE

Condition Name

Condition Name for PEMAZYRE
Intervention Trials
Acute Myeloid Leukemia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for PEMAZYRE
Intervention Trials
Leukemia 1
Leukemia, Myeloid, Acute 1
Leukemia, Myeloid 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for PEMAZYRE

Trials by Country

Trials by Country for PEMAZYRE
Location Trials
United States 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for PEMAZYRE
Location Trials
Oregon 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for PEMAZYRE

Clinical Trial Phase

Clinical Trial Phase for PEMAZYRE
Clinical Trial Phase Trials
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for PEMAZYRE
Clinical Trial Phase Trials
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for PEMAZYRE

Sponsor Name

Sponsor Name for PEMAZYRE
Sponsor Trials
Incyte Corporation 1
OHSU Knight Cancer Institute 1
Oregon Health and Science University 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for PEMAZYRE
Sponsor Trials
Other 2
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Colorcon
McKesson
AstraZeneca
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.